Sunesis is a biopharmaceutical company and performs research on targeting the oncology sector for the treatment of solid and haematologic cancers.
Sunesis has announced that USPTO has granted the formulation patent which covers the formulation of vosaroxin which is currently used in the clinical trials. The US patent no is 7,829,577 with expiry March 14, 2025. It is also eligible of extension , so term may be extended in future.
(Source: Pharmabiz)
No comments:
Post a Comment